Immuron Share Price Rises 16.9% as FY25 Global Sales Surge 49% YoY

Sonal Goyal

17 July 2025 12:25 PM AEST

Immuron Share Price Rises 16.9% as FY25 Global Sales Surge 49% YoY

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

IMC share price increased 16.9% to 7.6 cents per share on 17 July 2025.

FY25 global unaudited sales reached AUD 7.3 million, up 49% YoY.

Australia and North America recorded sales growth of 40% and 76%, respectively.

Immuron Limited (ASX:IMC; NASDAQ:IMRN) saw its share price rise by 16.9% to 7.6 cents per share on 17 July 2025 after announcing that global unaudited sales for FY25 reached AUD 7.3 million, representing a 49% increase over the previous year. The performance was led by continued demand for Travelan®, Immuron’s over-the-counter immune supplement, across both domestic and international markets.

In Australia, FY25 sales totalled AUD 5.2 million, marking a 40% increase compared to the prior year. Sales for the June 2025 quarter alone amounted to AUD 1.5 million, up 58% year-on-year. The growth was driven by a national pharmacy visibility program and increased consumer engagement, positioning Travelan as one of the fastest-growing brands in Australian pharmacies.

The North American market delivered even higher growth, with FY25 sales rising to AUD 2 million, up 76% from the previous year. Quarterly sales in the region reached AUD 0.5 million, a 49% increase year-on-year. This growth was attributed to successful Amazon sales in the U.S. and expanding distribution channels in Canada. Targeted communication campaigns highlighting the benefits of Travelan helped drive brand adoption and consumer purchases.

Flavio Palumbo, Chief Commercial Officer of Immuron, noted that FY25 marked record sales achievements in all regions, with the company’s strategic goal of positioning Travelan as an essential travel health product yielding positive results. He added that Immuron plans to further invest in North America in FY26 while maintaining its growth trajectory in Australia.

Immuron is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for inflammatory and infectious diseases.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.